Objective: Historically the rates of postpartum glucose tolerance testing for women with gestational diabetes (GDM) average a suboptimal 33%. Barriers include the need for new mothers to miss work and/or arrange for childcare in order to engage in a two-hour test at a commercial lab. This pilot study was initiated to test the theory that a home testing regimen would be accepted by patients and increase the rate of postpartum glucose assessments relative to published rates, without requiring additional health-care staff or resources to achieve this goal.
Introduction
After a pregnancy complicated by gestational diabetes (GDM), 20-30% of women have impaired glucose tolerance or persistent diabetes mellitus (DM), but the number of women returning for recommended testing is suboptimal, averaging 33% (range 9-95%). The incidence of GDM has doubled meaning more women are in need of testing. 6, [27] [28] [29] [30] Direct feedback from our patients and a focus group established that busy new mothers, many of whom return to the workforce, find the standard two-hour-75-gram oral glucose tolerance test (OGTT) inconvenient. 31 The American Diabetes Association, in the spirit of capturing those at risk, promoted the fasting plasma glucose (FPG), and the American College of Obstetrics and Gynecology (ACOG) also recommends an OGTT or a FPG. 1, 32 However, while FPG requires less of a time commitment, the sensitivity may be inadequate. 13, 26, 33, 34 The Agency for Healthcare Research and Quality (AHRQ) has defined diagnosis of DM after a history of GDM as a future research need for the management of GDM. 35, 36 In that context, and because women with GDM possess a glucose monitor that they used for at least the last 12 weeks of their pregnancy, we hypothesized that among women educated and familiar with home glucose monitoring, a postpartum home testing regimen consisting of eight home fingerstick blood glucose values (fasting, and 2 hours after each meal), taken over two days, eight-weeks postpartum (the Fingerstick Assessment of Sugars Two-months postpartum or FAST Protocol) would be accepted as convenient. The primary objective of this pilot study was to determine if the FAST protocol could increase the rate of postpartum glucose testing in this cohort, compared with historical controls.
Materials and methods

Population and standard treatment
This was a cohort study of consecutive English speaking women 418 years of age with GDM who were recruited at antepartum visits during 2007, or during an inpatient consult immediately after delivery from a private Obstetric Medicine Practice at St Peter's University Hospital in New Brunswick, NJ, USA. All women in the cohort had private insurance. The low overall testing rate at 12 months was interpreted as an indication that devoting additional time to patient recruitment and tracking outside of routine clinical care was not likely to yield meaningful results. That and the loss of a physician to a different practice were the reasons why recruitment was ended after one year.
Once diagnosed with GDM, patients received standard counselling about diet and monitoring of fingerstick sugars at home. ACOG guidelines call for glucose monitoring either one hour (goal 5130-140 mg/dL) (Box 1) or two hours (goal 5120 mg/dL) after meals. Based on the evidence that, relative to preprandial monitoring, postprandial monitoring was associated with lower rates of neonatal hypoglycemia, large for gestational age infants and caesarean delivery because of cephalopelvic disproportion, in our centres we monitor sugars four times a day: fasting, and two hours after each meal. 37, 38 If, despite adherence to the appropriate diet, fasting bloods sugar were consistently and significantly 495 mg/dL or postprandial blood sugar 4120 mg/dL, then pharmacological therapy was recommended with either glyburide or insulin. Blood sugars were faxed to our office each week, reviewed by a physician, feedback regarding the values was provided and patients were scheduled to be seen in the office by a physician at least once every four weeks until delivery. Demographic information was collected, including self-reported race category.
Postpartum protocol
When contacted by the obstetrician, the treating physicians saw the women in the hospital after delivery, reviewed the protocol, provided a prescription for an OGTT and provided an office appointment to review the results. They were instructed that six weeks postpartum they should check fingerstick blood glucose (FSBG) four times a day (fasting and 2 hours after meals) for two days (the FAST protocol), go for the OGTT a week later and follow up in the office at eight weeks to review the results. To improve compliance, they were provided with a sheet that listed the dates for the tests and office visit. The physicians reviewed the patient list and attempted to contact women whose due date had passed, or who had not followed up for the postpartum office visit to encourage them to complete the FAST protocol and obtain the postpartum OGTT. If contacted, patients were asked to provide a reason for non-adherence with the testing regimen. The FSBG values were reviewed at a follow-up visit as part of their routine care and no incentive was offered.
Endpoints
The primary endpoint was to increase the percentage of women in this cohort who had a postpartum glucose tolerance assessment above the historical average of 33%. The secondary endpoint was: if the percentage tested was higher than historical controls and those women complied with both tests (FAST and OGTT), the eight FAST glucose values would be analysed to determine cut-off point that could maximize the sensitivity of the new protocol to predict which women would have an abnormal OGTT.
Rationale for the FAST protocol
This was initiated within a private practice setting without additional staff or resources. To facilitate convenience and generalizability, women were not given a specific glucose load, so we hypothesized that (a) eight values could balance sensitivity versus specificity, and (b) two days would seem reasonable to patients who had checked sugars four times a day for 12 weeks, and therefore would promote compliance.
The effect of fragmented care was avoided as the treating physicians were responsible for arranging postpartum testing and seeing the patients to review the results. IRB approval was obtained. No funding was received. A specific rate of postpartum follow-up was not targeted as this was a pilot study. All assessments and follow up were conducted by the study physicians. Stata 9.0 (Statcorp, College Station, TX, USA) was used to calculate mean values with standard deviations; mean values were compared using t-test or Wilcoxon-Rank Sum for non-parametric data.
Results
All women had private medical insurance: 69 were approached, two refused enrolment. Self-described race categories were available on 63/67 women, and they were diverse ( Table 1 ). The mean gravidity was 2 (range 0-9) and the mean number of live children was 1 (range 0-3). Twenty (34%) of the women with a prior pregnancy had GDM, and 14/20 required insulin in the past. There were no significant differences in mean age, BMI or gestational age at enrolment.
In spite of monthly antepartum appointments and weekly reminder phone calls by the treating physicians, of the 67 participants only 20 (30%) had any kind of postpartum testing (FAST or OGTT). Twelve (18%) completed both an OGTT and the FAST protocol, five (7%) only the FAST protocol and three only the OGTT (Figure 1 ). The other women declined further testing or ignored attempts to arrange follow-up. The demands of caring for a newborn or the annoyances of fingersticks were cited by the women as deterrents to completing any kind of postpartum testing. None of the women contacted stated loss of health insurance, but not all non-compliant women were able to be contacted and others did not return messages.
The rate of testing for women treated with diet alone was 36% while it was 28% for those treated with a medication (insulin or glyburide). Parity did not appear to influence the follow-up rate as the mean number of live children at home was not different between those that followed up and those that did not (Table 1 ). More women who did not return for testing had a family history of diabetes than women who did return, but the difference was not significant, 2 P ¼ 0.09 (Table 1) .
From the FAST results, all fasting sugars were 99 mg/dL and among the 12 women who completed both the FAST protocol and the OGTT, there were six with a FAST value !104 mg/dL (Figure 1 ). Five of those (patients 1, 3, 5, 8 and 12) had only a single value !104 mg/dL and all had a normal OGTT; Patient 2 had three values !104 mg/dL with impaired glucose tolerance. The postprandial blood sugars ranged from 70 to 185 mg/dL. If the definition of an 'abnormal' FAST protocol was set as three values !104 mg/dL, compared with the OGTT, the specificity is 100% (95% confidence interval [C.I.] 72-100%). However, the sensitivity is 100%, with an impractically large 95% CI of 2.5-100% indicating that the sample size is too small to allow conclusions about the clinical utility of this protocol.
Conclusions
In spite of avoiding fragmentation of care during the ante-and postpartum periods the FAST home-testing protocol, compared with historical rates, did not facilitate an increase in the rate of postpartum glucose assessments within this GDM cohort. Five women who did not go for an OGTT followed the FAST protocol (7.4% absolute increase in postpartum glucose assessments, relative increase of 33%). However, this increase is tempered by the fact that the total rate was similar to historical controls. Additionally, the analysis of those who went for both tests yielded a wide confidence interval regarding the sensitivity. The FBG was 599 mg/dL in the one woman with impaired glucose tolerance.
Prior studies have found that use of insulin was associated with higher rates of postpartum glucose intolerance and compliance with screening rates, but the use of medication was not associated with a different rate of testing in this study. 39 Although not statically significant, compared with those who returned for testing, more of those who did not return had a family history of diabetes. This is consistent with Box 1. Convert mg/dL to mmol/L. 120 mg/dL ¼ 6.7 mmol/L 130-140 mg/dL ¼ 7.2-7.8 mmol/L mg/dL Â 0.0555 ¼ mmol/L mmol/L Â 18.0182 ¼ mg/dL findings from a focus group that identified feelings of emotional stress due to adjusting to a new baby, and the fear of receiving a diabetes diagnosis at the visit as barriers to attending follow-up appointments. 31 A number of articles and reviews have listed conflicting findings regarding specific patient demographics and associations with postpartum testing rates, such as Hispanic women being tested 2% more or 10% less than White women. We think broader system-based changes are needed to improve testing, subsequently we did not analyse every patient demographic for an association with testing. 2, 39 Post hoc, it is possible that the request to obtain eight home glucose values, as opposed to a lower number, was a reason for non-compliance. However, the objective was to evaluate if two more days would be perceived as a significant burden after 12 weeks of monitoring. More data points would provide additional power for a potential sensitivity/specificity analysis. Criticizing eight finger-stick values as being an insensitive diagnostic tool only leaves one with a single value FBG, a test reported to have a wide range of sensitivity or the OGTT, a test with a low-compliance rate.
The request to obtain two postpartum tests could have been an impediment, but because only five women completed the FAST protocol and not the OGTT, it appears that the need to go to a lab was not the primary barrier for the 47 women who did not complete any kind of postpartum testing. This is contrary to our working hypothesis. Additionally, direct postpartum phone calls did not improve the rate, and treatment with medication was not associated with a differential response further suggesting that those 47 were not motivated regardless of where it was done. Theoretically, extending the time for postpartum testing beyond 6-12 weeks could improve testing rates, but interestingly our literature review determined this is not the case.
Retrospective studies reporting historical testing rates at 6-months (36%) and 1-year (33%) were the same as those reporting short-term follow-up (35%). 14, 40, 41 Prospective studies allocating staff to patient contact systems, a resource we did not have, increased the testing rates to an average of 60% in all time frames. 2, 42, 43 However, based on a prospective randomized trial, these rates could be due to the timeframe in which patient contact efforts are focused. This Canadian project demonstrated that sending reminder letters to the patient and/or their primary care physicians up to one year after delivery increased the testing rate from 14% (no letter sent) up to 60% (letter sent to patient and physician). 25 Any new protocol effective at improving testing rates would have to be considered convenient, but would not require perfect sensitivity compared with the OGTT. If a new postpartum regimen was only 90% sensitive, but women assigned to it had a follow-up rate 50% higher than the OGTT group, the higher compliance would facilitate detection of a greater number of women with impaired glucose tolerance or DM.
In conclusion, this home testing regimen, while in line with the AHRQ future research need for GDM, was not associated with an overall postpartum testing rate higher than historical controls. A few more women completed the home testing portion suggesting that future efforts utilizing home testing could bypass some barriers, but not all. The prevalence of obesity, DM and GDM are increasing, therefore continued innovation is required to address the many barriers to postpartum testing and develop new protocols that will promote higher testing rates and identification of women with pre-or overt diabetes.
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